Loading…
Ensuring Safe Access to Prescription Medication Act of 2014
Legislative Progress
Introduced
September 16, 2014
Latest Action
September 16, 2014
Primary Sponsor
Sherrod BrownDemocratic(OH)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,002 other S bills in the 113th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2017 · first_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Pharmacy
Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
S.2825 - issues relating to the delivery of a controlled substance by a pharmacy to a practitioner
Client expense: $950,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
S. 2825 relating to the delivery of a controlled substance to the practitioner by the pharmacy
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Ensuring Safe Access to Prescription Medication Act of 2014 S.2825
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
S.2825 - issues relating to the delivery of a controlled substance by a pharmacy to a practitioner
Client expense: $1,420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Pharmaceutical Compounding Quality and Accountability Act; The Compounding Clarity Act; Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
S. 2825 relating to the delivery of a controlled substance by a pharmacy to a practitioner
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE